

DOCKET NO: 278868US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
NOBUAKI ETO, ET AL. : EXAMINER: ROBINSON, BINTA M.
SERIAL NO: 10/550,857 :
FILED: APRIL 10, 2006 : GROUP ART UNIT: 1625
FOR: COMPOUND INHIBITING IN VIVO :
PHOSPHORUS TRANSPORT AND
MEDICINE CONTAINING THE SAME

RESPONSE TO THE REQUIREMENT FOR RESTRICTION

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:


In response to the Requirement for Restriction mailed October 21, 2008, Applicants elect, without traverse, Group I: Claims 1-76 drawn to a product. As the species, Applicants elect Compound 863, 3 {[2-(diethylamino-ethyl)-methyl amino]-methyl}-N-[2,4-methoxy-benzylidene-hydrazino carbonyl -4-piperdin-1-yl-phenyl]-benzamide, which can be found on pages 422 and 519 of the specification. The claims readable on this election include Claims 1-76 with the exception of Claims 17-23, 53-55 and 59-65.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)


James H. Knebel